NFL Biosciences SA
EEURONEXT:ALNFL0.54
EUR
-0.02
(-4.29%)
ISIN
FR0014003XT0
Return %
Stock
S&P 500
1Y
-51.27
14.39
3Y
-52.57
81.42
5Y
-86.19
68.62
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Bruno Lafont
- Full Time Employees
- 4
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 199 Rue Helene Boucher Castelnau-le-Lez OCC France 34170
- IPO Date
- Jul 5, 2021
- Website
- nflbiosciences.com
- Similar Companies
- Business
- NFL Biosciences S.A. (ALNFL.PA) is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions, including tobacco use disorder and excessive alcohol consumption; its lead product, NFL-101, is a patented, nicotine-free tobacco leaf protein extract in Phase 2b clinical trials for smoking cessation with positive results published in Nicotine & Tobacco Research confirming reduced craving and prolonged efficacy; NFL-301 targets alcohol use reduction and is in preclinical development from a traditional Chinese medicine plant; the company employs an outsourced research model to advance its pipeline toward licensing to larger pharmaceutical partners. Founded in 2006 and headquartered at 199 Rue Hélène Boucher, Castelnau-le-Lez, France, NFL Biosciences operates primarily in Europe with international clinical ambitions including FDA interactions in the United States. Recent developments include a successful €3 million capital increase in May 2025 following an initial €2.2 million offering; €1.2 million in non-dilutive funding secured in July 2025 from Bpifrance and banking partners to support NFL-101 manufacturing, preclinical work, and Phase 3 preparation; scientific collaborations with McLean Hospital and CEA yielding new mechanism-of-action data and prolonged activity insights; expansion of its scientific committee with global experts and appointment of a Chief Medical Officer in 2025; and receipt of scientific advice from European agencies and the FDA in October 2025 outlining NFL-101's development plan.